Julia Marie Eastland
Julia Marie Eastland's purchase track record
Julia Marie Eastland has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/31/2025 | ZNTL | $49K | -16.7% | -23.0% | +3.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
Transaction History
| LNTH | ▲ Buy | Grant | 4,137 | $0 | 5/14/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 889 | $2K | 2/9/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 7,866 | $19K | 2/6/2026 | View on chart |
| LNTH | ▲ Buy | Grant | 2,537 | $0 | 5/14/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 59,388 | $0 | 2/3/2025 | View on chart |
| ZNTL | ▲ Buy | Open Market | 28,500 | $49K | 1/31/2025 | View on chart |
| LNTH | ▲ Buy | Grant | 1,345 | $0 | 9/10/2024 | View on chart |
| CALC | ▼ Sell | Other | 1,429 | — | 3/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Lantheus Holdings receives Mizuho downgrade to neutral
Lantheus Holdings was downgraded to neutral by Mizuho, which also cut its price target to $109. The downgrade appeared alongside other recent analyst cuts highlighted in a Benzinga roundup of top downgrades. The new target sits near the current analyst consensus of $107.22 and close to the stock’s 52‑week high, while the RSI is around the midpoint.
Lantheus Holdings receives Mizuho downgrade to neutral. Lantheus Holdings was downgraded to neutral by Mizuho, which also cut its price target to $109. The downgrade appeared alongside other recent analyst cuts highlighted in a Benzinga roundup of top downgrades. The new target sits near the current analyst consensus of $107.22 and close to the stock’s 52‑week high, while the RSI is around the midpoint.